Stifel Canada Comments on TSE:MDP FY2026 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Stifel Canada issued their FY2026 earnings per share estimates for Medexus Pharmaceuticals in a note issued to investors on Thursday, February 6th. Stifel Canada analyst J. Keywood anticipates that the company will post earnings of $0.10 per share for the year. Stifel Canada currently has a “Hold” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Other research analysts have also recently issued research reports about the company. Ventum Financial raised their price target on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Stifel Nicolaus cut shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their target price for the company from C$6.00 to C$3.45 in a research report on Friday, February 7th. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a research report on Wednesday, January 8th. Finally, Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, Medexus Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of C$5.49.

Medexus Pharmaceuticals Price Performance

Shares of TSE MDP opened at C$3.25 on Monday. The business has a fifty day moving average price of C$3.55 and a two-hundred day moving average price of C$2.84. The stock has a market capitalization of C$79.72 million, a PE ratio of 65.00 and a beta of 1.96. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.